OBJECTIVE: To determine the effects of long-term methylphenidate treatment on symptom severity and social adjustment in adult ADHD. METHOD: Adults (n = 116) meeting operational diagnostic criteria for ADHD (the "Utah Criteria") entered a randomized double-blind crossover trial of methylphenidate and placebo. Participants who improved on immediate-release methylphenidate entered a 12-month, open-label trial. Outcomes were assessed using the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), Clinical Global Impression-Improvement (CGI-I), global assessment of functioning (GAF), and the Weissman Social Adjustment Scale (WSAS). RESULTS: In the double-blind trial more patients improved (50% reduction of symptoms) receiving methylphenidate (74%) than placebo (21%, p = .001). During the open-label trial, symptom severity decreased 80% from baseline, and the WSAS decreased >50% in all subscales. The average GAF improved significantly (p < .0001). CONCLUSION:ADHD adults, who responded to methylphenidate in a short-tem, placebo-controlled trial, responded to long-term treatment with marked improvements in ADHD symptoms and psychosocial functioning.
RCT Entities:
OBJECTIVE: To determine the effects of long-term methylphenidate treatment on symptom severity and social adjustment in adult ADHD. METHOD: Adults (n = 116) meeting operational diagnostic criteria for ADHD (the "Utah Criteria") entered a randomized double-blind crossover trial of methylphenidate and placebo. Participants who improved on immediate-release methylphenidate entered a 12-month, open-label trial. Outcomes were assessed using the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), Clinical Global Impression-Improvement (CGI-I), global assessment of functioning (GAF), and the Weissman Social Adjustment Scale (WSAS). RESULTS: In the double-blind trial more patients improved (50% reduction of symptoms) receiving methylphenidate (74%) than placebo (21%, p = .001). During the open-label trial, symptom severity decreased 80% from baseline, and the WSAS decreased >50% in all subscales. The average GAF improved significantly (p < .0001). CONCLUSION:ADHD adults, who responded to methylphenidate in a short-tem, placebo-controlled trial, responded to long-term treatment with marked improvements in ADHD symptoms and psychosocial functioning.
Authors: J R Valdizán-Usón; A Cánovas-Martínez; M T De Lucas-Taracena; F Díaz-Atienza; L S Eddy-Ives; A Fernández-Jaén; M Fernández-Pérez; M García-Giral; P García-Magán; M Garraus-Oneca; M A Idiazábal-Alecha; M López-Benito; G Lorenzo-Sanz; J Martínez-Antón; M A Martínez-Granero; F Montañés-Rada; F Mulas-Delgado; G Ochando-Perales; E Ortega-García; A Pelaz-Antolín; J A Ramos-Quiroga; F C Ruiz-Sanz; J Vaquerizo-Madrid; A Yusta-Izquierdo Journal: Neuropsychiatr Dis Treat Date: 2013-02-08 Impact factor: 2.570
Authors: Wolfgang Retz; Michael Rösler; Claudia Ose; André Scherag; Barbara Alm; Alexandra Philipsen; Roland Fischer; Richard Ammer Journal: World J Biol Psychiatry Date: 2010-12-14 Impact factor: 4.132
Authors: Jan K Buitelaar; Götz-Erik Trott; Maria Hofecker; Sandra Waechter; Joris Berwaerts; Joachim Dejonkheere; Barbara Schäuble Journal: Int J Neuropsychopharmacol Date: 2011-07-29 Impact factor: 5.176